Andrew M Jones

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8728002/publications.pdf

Version: 2024-02-01

108 papers	3,429 citations	172457 29 h-index	149698 56 g-index
110 all docs	110 docs citations	110 times ranked	4952 citing authors

#	Article	IF	Citations
1	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354, 751-757.	12.6	462
2	Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. Journal of Clinical Investigation, 2011, 121, 3554-3563.	8.2	272
3	Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet, The, 2001, 358, 557-558.	13.7	234
4	Novel immunologic classification of aspergillosis in adult cystic fibrosis. Journal of Allergy and Clinical Immunology, 2013, 132, 560-566.e10.	2.9	180
5	Evolving epidemiology ofPseudomonas aeruginosaand theBurkholderia cepaciacomplex in cystic fibrosis lung infection. Future Microbiology, 2007, 2, 153-164.	2.0	144
6	Impact of treatment for opioid dependence on fatal drugâ€related poisoning: a national cohort study in England. Addiction, 2016, 111, 298-308.	3.3	124
7	Incidence and clinical impact of respiratory viruses in adults with cystic fibrosis. Thorax, 2014, 69, 247-253.	5.6	107
8	Emerging Treatments in Cystic Fibrosis. Drugs, 2009, 69, 1903-1910.	10.9	94
9	Gene expression changes linked to antimicrobial resistance, oxidative stress, iron depletion and retained motility are observed when Burkholderia cenocepaciagrows in cystic fibrosis sputum. BMC Infectious Diseases, 2008, 8, 121.	2.9	85
10	Effects of Ivacaftor in Patients With Cystic Fibrosis Who Carry the G551D Mutation and Have Severe Lung Disease. Chest, 2014, 146, 152-158.	0.8	85
11	Rapid Detection of Emerging Pathogens and Loss of Microbial Diversity Associated with Severe Lung Disease in Cystic Fibrosis. Journal of Clinical Microbiology, 2015, 53, 2022-2029.	3.9	82
12	Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells. Thorax, 2011, 66, 333-339.	5.6	74
13	Do All Patients Require Supplemental Oxygen During Flexible Bronchoscopy?. Chest, 2001, 119, 1906-1909.	0.8	72
14	IgE-Mediated Immune Responses and Airway Detection of Aspergillus and Candida in Adult Cystic Fibrosis. Chest, 2013, 143, 1351-1357.	0.8	71
15	Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without Pseudomonas aeruginosa infection. Journal of Breath Research, 2013, 7, 026010.	3.0	63
16	Intravenous antibiotics reduce the presence ofAspergillusin adult cystic fibrosis sputum. Thorax, 2013, 68, 652-657.	5.6	62
17	Prospective Surveillance forPseudomonas aeruginosaCross-Infection at a Cystic Fibrosis Center. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 257-260.	5.6	52
18	Long-term non-invasive ventilation in cystic fibrosis â€" Experience over two decades. Journal of Cystic Fibrosis, 2012, 11, 187-192.	0.7	47

#	Article	IF	Citations
19	Clinical Outcome for Cystic Fibrosis Patients Infected With Transmissible Pseudomonas aeruginosa : An 8-Year Prospective Study. Chest, 2010, 137, 1405-1409.	0.8	42
20	Homogenisation of cystic fibrosis sputum by sonication â€" An essential step for Aspergillus PCR. Journal of Microbiological Methods, 2011, 85, 75-81.	1.6	42
21	Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis. Journal of Cystic Fibrosis, 2004, 3, 233-236.	0.7	41
22	The Microbiome and Emerging Pathogens in Cystic Fibrosis and Nonâ€"Cystic Fibrosis Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 225-235.	2.1	41
23	Exhaled breath hydrogen cyanide as a marker of earlyPseudomonas aeruginosainfection in children with cystic fibrosis. ERJ Open Research, 2015, 1, 00044-2015.	2.6	40
24	Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. The Cochrane Library, 2016, , CD009529.	2.8	39
25	Can Early Burkholderia cepacia Complex Infection in Cystic Fibrosis be Eradicated with Antibiotic Therapy?. Frontiers in Cellular and Infection Microbiology, 2011, 1, 18.	3.9	38
26	An investigation of suitable bag materials for the collection and storage of breath samples containing hydrogen cyanide. Journal of Breath Research, 2012, 6, 036004.	3.0	36
27	Sweat chloride is not a useful marker of clinical response to Ivacaftor. Thorax, 2014, 69, 586-587.	5.6	35
28	Itraconazole and inhaled fluticasone causing hypothalamicâ€"pituitaryâ€"adrenal axis suppression in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2013, 12, 399-402.	0.7	33
29	Identification of DNA Markers for a TransmissiblePseudomonas aeruginosaCystic Fibrosis Strain. American Journal of Respiratory Cell and Molecular Biology, 2005, 33, 56-64.	2.9	32
30	Antibiotic treatment forBurkholderia cepaciacomplex in people with cystic fibrosis experiencing a pulmonary exacerbation. , 2012, 10, CD009529.		30
31	Quantification of hydrogen cyanide and 2-aminoacetophenone in the headspace of Pseudomonas aeruginosa cultured under biofilm and planktonic conditions. Analytical Methods, 2012, 4, 3661.	2.7	27
32	Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?. Thorax, 2015, 70, 615-616.	5.6	27
33	A general protein O-glycosylation machinery conserved in Burkholderia species improves bacterial fitness and elicits glycan immunogenicity in humans. Journal of Biological Chemistry, 2019, 294, 13248-13268.	3.4	27
34	Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids. Journal of Cystic Fibrosis, 2012, 11, 458-460.	0.7	26
35	Pseudomonas aeruginosa cross-infection in cystic fibrosis. Lancet, The, 2002, 359, 527.	13.7	24
36	The diagnosis and management of respiratory viral infections in cystic fibrosis. Expert Review of Respiratory Medicine, 2017, 11, 221-227.	2.5	23

#	Article	IF	Citations
37	The changing epidemiology of Burkholderia species infection at an adult cystic fibrosis centre. Journal of Cystic Fibrosis, 2008, 7, 368-372.	0.7	22
38	Emerging Gram-negative bacteria. Current Opinion in Pulmonary Medicine, 2018, 24, 592-598.	2.6	22
39	Isolation, motivation and balance: living with type 1 or cystic fibrosis-related diabetes. Journal of Clinical Nursing, 2008, 17, 235-243.	3.0	21
40	Anaerobic bacteria in cystic fibrosis: pathogens or harmless commensals?. Thorax, 2011, 66, 558-559.	5.6	21
41	What is the importance of classifyingAspergillusdisease in cystic fibrosis patients?. Expert Review of Respiratory Medicine, 2014, 8, 389-392.	2.5	21
42	Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. The Cochrane Library, 2020, 4, CD009529.	2.8	20
43	Longitudinal effects of ivacaftor and medicine possession ratio in people with theGly551Aspmutation: a 5-year study. Thorax, 2021, 76, 874-879.	5.6	20
44	Reassessment of the importance of mucins in determining sputum properties in cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 260-266.	0.7	18
45	Liminality and transfer to adult services: A qualitative investigation involving young people with cystic fibrosis. International Journal of Nursing Studies, 2013, 50, 738-746.	5.6	17
46	Is Hydrogen Cyanide a Marker of Burkholderia cepacia Complex?. Journal of Clinical Microbiology, 2013, 51, 3849-3851.	3.9	17
47	Noninvasive assessment of subclinical atherosclerosis in persons with symptoms of depression. Atherosclerosis, 2017, 264, 92-99.	0.8	17
48	Chronic Rhinovirus Infection in an Adult with Cystic Fibrosis. Journal of Clinical Microbiology, 2013, 51, 3893-3896.	3.9	16
49	Living with cystic fibrosis-related diabetes or type 1 diabetes mellitus: a comparative study exploring health-related quality of life and patients' reported experiences of hypoglycaemia. Chronic Illness, 2008, 4, 278-288.	1.5	14
50	New and Emerging Treatments for Cystic Fibrosis. Drugs, 2015, 75, 1165-1175.	10.9	14
51	Increased prevalence of Pneumocystis jirovecii colonisation in acute pulmonary exacerbations of cystic fibrosis. Journal of Infection, 2016, 73, 1-7.	3.3	14
52	CFTR modulator therapy in patients with cystic fibrosis and an organ transplant. Paediatric Respiratory Reviews, 2018, 27, 6-8.	1.8	13
53	Which pathogens should we worry about?. Paediatric Respiratory Reviews, 2019, 31, 15-17.	1.8	13
54	Effectiveness of inpatient withdrawal and residential rehabilitation interventions for alcohol use disorder: A national observational, cohort study in England. Journal of Substance Abuse Treatment, 2018, 88, 1-8.	2.8	12

#	Article	IF	Citations
55	Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin. Journal of Cystic Fibrosis, 2007, 6, 209-211.	0.7	10
56	Temocillin in cystic fibrosis: A retrospective pilot study. Journal of Cystic Fibrosis, 2008, 7, 551-554.	0.7	10
57	Pneumothorax in cystic fibrosis: beyond the guidelines. Paediatric Respiratory Reviews, 2016, 20, 30-33.	1.8	10
58	Effectiveness of community psychosocial and pharmacological treatments for alcohol use disorder: A national observational cohort study in England. Drug and Alcohol Dependence, 2018, 186, 60-67.	3.2	10
59	Assessing arthritis in the context of cystic fibrosis. Pediatric Pulmonology, 2019, 54, 770-777.	2.0	10
60	Structured surveillance of Achromobacter, Pandoraea and Ralstonia species from patients in England with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 388-393.	0.7	10
61	Review article: epidemiology, pathogenesis and management of liver disease in adults with cystic fibrosis. Alimentary Pharmacology and Therapeutics, 2022, 55, 389-400.	3.7	10
62	High level of Î²-(1,3)- d -glucan antigenaemia in cystic fibrosis in the absence of invasive fungal disease. Diagnostic Microbiology and Infectious Disease, 2017, 88, 316-321.	1.8	9
63	Managing Pulmonary Infection in Adults With Cystic Fibrosis. Chest, 2022, 162, 66-75.	0.8	9
64	Diagnosis and management of non-cystic fibrosis bronchiectasis. Clinical Medicine, 2021, 21, e571-e577.	1.9	8
65	Improvement in Exophiala dermatitidis airway persistence and respiratory decline in response to interferon-gamma therapy in a patient with cystic fibrosis. Journal of Cystic Fibrosis, 2018, 17, e32-e34.	0.7	7
66	Burkholderia latens infection in cystic fibrosis. Journal of Cystic Fibrosis, 2011, 10, 291-292.	0.7	6
67	Gout and hyperuricaemia in adults with cystic fibrosis. Journal of the Royal Society of Medicine, 2011, 104, 36-39.	2.0	6
68	Influenza B outbreak at an adult cystic fibrosis centre - Clinical impact and factors influencing spread. Journal of Cystic Fibrosis, 2020, 19, 808-814.	0.7	6
69	Sputum trypsin-like protease activity relates to clinical outcome in cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 647-653.	0.7	6
70	Meteorological Factors Influence the Presence of Fungi in the Air; A 14-Month Surveillance Study at an Adult Cystic Fibrosis Center. Frontiers in Cellular and Infection Microbiology, 2021, 11, 759944.	3.9	6
71	A therapeutic conundrum: recurrent cystic-fibrosis-related haemoptysis complicated by acute pulmonary embolism: Figure 1. Thorax, 2012, 67, 931-932.	5.6	5
72	Persistent oseltamivir-resistant pandemic influenza A/H1N1 infection in an adult with cystic fibrosis. BMJ Case Reports, 2011, 2011, bcr0220113874-bcr0220113874.	0.5	5

#	Article	IF	Citations
73	Recent advances in cross-infection in cystic fibrosis: Burkholderia cepacia complex, Pseudomonas aeruginosa, MRSA and Pandoraea spp. Journal of the Royal Society of Medicine, 2003, 96 Suppl 43, 66-72.	2.0	5
74	Adults with Cystic Fibrosis Should be Treated at a Specialist Centre. Paediatric Respiratory Reviews, 2013, 14, 13-15.	1.8	4
75	Diabetic retinopathy in patients who do not meet the diagnostic criteria for cystic fibrosis related diabetes. Practical Diabetes, 2015, 32, 333-335a.	0.3	4
76	A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 695-701.	0.7	4
77	Tobacco Smoking Rates in a National Cohort of People with Substance Use Disorder Receiving Treatment. European Addiction Research, 2021, 27, 151-155.	2.4	4
78	Lung clearance index in healthy volunteers, measured using a novel portable system with a closed circuit wash-in. PLoS ONE, 2020, 15, e0229300.	2.5	4
79	Did paying drugs misuse treatment providers for outcomes lead to unintended consequences for hospital admissions? Differenceâ€inâ€differences analysis of a payâ€forâ€performance scheme in England. Addiction, 2021, 116, 3082-3093.	3.3	4
80	Development of a modern adult cystic fibrosis centre in Manchester. Journal of the Royal Society of Medicine, 2010, 103, 15-19.	2.0	3
81	Anabolic agent use in adults with cystic fibrosis. Paediatric Respiratory Reviews, 2015, 16, 28-30.	1.8	3
82	Levels of Motivation and Readiness for Treatment Aligned With Criminal Justice Referral and Coercion Among Substance Users in England. Journal of Studies on Alcohol and Drugs, 2017, 78, 884-888.	1.0	3
83	Ivacaftor for cystic fibrosis. BMJ: British Medical Journal, 2018, 361, k1783.	2.3	3
84	Investigation of a Pandoraea apista cluster common to adult and paediatric cystic fibrosis patients attending two hospitals in the same city. Journal of Medical Microbiology, 2019, 68, 1081-1095.	1.8	3
85	Pseudomonas aeruginosa bacteraemia in an adult with cystic fibrosis and acute appendicitis. Journal of Cystic Fibrosis, 2011, 10, 477-478.	0.7	2
86	Monitoring of tobramycin levels in patients with cystic fibrosis by finger-prick sampling: Figure 1â€“. European Respiratory Journal, 2012, 39, 1537-1538.	6.7	2
87	Airborne dissemination of transmissible bacterial species in cystic fibrosis. Thorax, 2014, 69, 690-691.	5.6	2
88	Panton-Valentine Leukocidin-positive Staphylococcus aureus: a potentially significant pathogen in cystic fibrosis. Paediatric Respiratory Reviews, 2014, 15, 22-25.	1.8	2
89	Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis. Seminars in Respiratory and Critical Care Medicine, 2015, 36, 167-168.	2.1	2
90	Development of a resource allocation formula for substance misuse treatment services. Journal of Public Health, 2018, 40, e396-e404.	1.8	2

#	Article	IF	Citations
91	Isolation of Exophiala dermatitidis is not associated with worse clinical outcomes during acute pulmonary exacerbations in cystic fibrosis. Journal of Medical Microbiology, 2022, 71, .	1.8	2
92	Supplemental Oxygen During Flexible Bronchoscopy. Chest, 2002, 121, 664.	0.8	1
93	Estimates of the Incidence of Crack Cocaine Use in Those Likely to Attend Treatment in the English Population, 2005â€“2018. European Addiction Research, 2021, 27, 83-86.	2.4	1
94	Underwater Photography in the Human Airway. Chest, 2002, 122, 384-385.	0.8	0
95	Calcium Stone Growth in Urine from Cystic Fibrosis Patients and Healthy Controls. AIP Conference Proceedings, 2007, , .	0.4	0
96	Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin. Journal of Cystic Fibrosis, 2014, 13, 754.	0.7	0
97	Royal society of medicine cystic fibrosis symposium 2017. Paediatric Respiratory Reviews, 2018, 27, 1.	1.8	0
98	The diagnosis of Cystic Fibrosis: Controversies and consensus on common grounds. Paediatric Respiratory Reviews, 2019, 31, 1-2.	1.8	0
99	After the Celebrations: Lessons from the New Era of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy. Annals of the American Thoracic Society, 2019, 16, 189-190.	3.2	0
100	Royal Society of Medicine Cystic Fibrosis Symposium 2019. Paediatric Respiratory Reviews, 2020, 35, 88-89.	1.8	0
101	Fungal lung disease. , 0, , 186-203.		0
102	Daily sitting time and its association with non-communicable diseases and multimorbidity in Catalonia. European Journal of Public Health, 2022, 32, 105-111.	0.3	0
103	Title is missing!. , 2020, 15, e0229300.		0
104	Title is missing!. , 2020, 15, e0229300.		0
105	Title is missing!. , 2020, 15, e0229300.		0
106	Title is missing!. , 2020, 15, e0229300.		0
107	Title is missing!. , 2020, 15, e0229300.		0
108	Title is missing!. , 2020, 15, e0229300.		0